Taizo Hibi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taizo Hibi has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Yuko Kitagawa
Department of Surgery, Keio University School of Medicine , Tokyo
14 shared publications - Yuta Abe
Department of Surgery Keio University School of Medicine Tokyo Japan
14 shared publications Masahiro Shinoda
11 shared publicationsMinoru Kitago
10 shared publications- Hiroshi Yagi
Department of Surgery, Keio University School of Medicine, Tokyo, Japan
9 shared publications - Osamu Itano
Department of Surgery, Keio University School of Medicine, Tokyo, Japan
7 shared publications
Latest Publications
- 31 October 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 10 (4) , 93-96
Small‐for‐size syndrome in LT
- 31 October 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 10 (4) , 93-96
Small‐for‐size syndrome in LT
- 1 May 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (5S-3) , S17
Development of Transplantable Engineered Graft by Organ Derived Acellular Frame
- 1 May 2017
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (5S-3) , S17
Development of Transplantable Engineered Graft by Organ Derived Acellular Frame
- 1 September 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (5) , 922-930
Endocrine pancreas engineered using porcine islets and partial pancreatic scaffolds
- 1 September 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (5) , 922-930
Endocrine pancreas engineered using porcine islets and partial pancreatic scaffolds
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S65
Beneficial effects and long-term outcomes of neoadjuvant chemoradiotherapy with 5-fluoruracil, cisplatin, mitomycin C, and heparin for pancreatic cancer
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S65
Beneficial effects and long-term outcomes of neoadjuvant chemoradiotherapy with 5-fluoruracil, cisplatin, mitomycin C, and heparin for pancreatic cancer
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S140
Clinical utility of FDG-PET in preoperative evaluation of pancreatic neuroendocrine tumors
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S140
Clinical utility of FDG-PET in preoperative evaluation of pancreatic neuroendocrine tumors
- 29 April 2016
- Published by Springer Nature in Surgery Today
- Vol. 47 (4) , 403-415
Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun
The indications of liver transplantation for hepatobiliary malignancies have been carefully expanded in a stepwise fashion, despite the fundamental limitations in oncological, immunological, and technical aspects. A new era of “Transplant Oncology,” the fusion of transplant surgery and surgical oncology, has begun, and we stand at the dawn of a paradigm shift in multidisciplinary cancer treatment. For hepatocellular carcinoma, new strategies have been undertaken to select recipients based on biological and dynamic markers instead of conventional morphological and static parameters, opening the doors for a more deliberate expansion of the Milan criteria and locoregional therapies before liver transplantation. Neoadjuvant chemoradiation therapy followed by liver transplantation for unresectable perihilar cholangiocarcinoma developed by the Mayo Clinic provided excellent outcomes in a US multicenter study; however, the surgical indications are not necessarily universal and await international validation. Similarly, an aggressive multidisciplinary approach has been applied for other tumors, including intrahepatic cholangiocarcinoma, hepatoblastoma, liver metastases from colorectal and neuroendocrine primary and gastrointestinal stromal tumors as well as rare tumors, such as hepatic undifferentiated embryonal sarcoma and infantile choriocarcinoma. In conclusion, liver transplantation is an important option for hepatobiliary malignancies; however, prospective studies are urgently needed to ensure the appropriate patient selection, organ allocation and living donation policies, and administration of antineoplastic immunosuppression.
- 29 April 2016
- Published by Springer Nature in Surgery Today
- Vol. 47 (4) , 403-415
Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun
The indications of liver transplantation for hepatobiliary malignancies have been carefully expanded in a stepwise fashion, despite the fundamental limitations in oncological, immunological, and technical aspects. A new era of “Transplant Oncology,” the fusion of transplant surgery and surgical oncology, has begun, and we stand at the dawn of a paradigm shift in multidisciplinary cancer treatment. For hepatocellular carcinoma, new strategies have been undertaken to select recipients based on biological and dynamic markers instead of conventional morphological and static parameters, opening the doors for a more deliberate expansion of the Milan criteria and locoregional therapies before liver transplantation. Neoadjuvant chemoradiation therapy followed by liver transplantation for unresectable perihilar cholangiocarcinoma developed by the Mayo Clinic provided excellent outcomes in a US multicenter study; however, the surgical indications are not necessarily universal and await international validation. Similarly, an aggressive multidisciplinary approach has been applied for other tumors, including intrahepatic cholangiocarcinoma, hepatoblastoma, liver metastases from colorectal and neuroendocrine primary and gastrointestinal stromal tumors as well as rare tumors, such as hepatic undifferentiated embryonal sarcoma and infantile choriocarcinoma. In conclusion, liver transplantation is an important option for hepatobiliary malignancies; however, prospective studies are urgently needed to ensure the appropriate patient selection, organ allocation and living donation policies, and administration of antineoplastic immunosuppression.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 353
Phase I study of neoadjuvant S-1 plus cisplatin with concurrent radiation for biliary tract cancer (KOBTC02).
353 Background: Although surgery plays a key role in the curative treatment for biliary tract cancer (BTC), the prognosis is not satisfactory because of frequent postoperative recurrence. Multimodal treatment has been warranted in order to improve this situation. The aim of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of cisplatin as neoadjuvant chemoradiotherapy with S-1 and external beam radiation for BTC. Methods: Patients with resectable BTC at initial diagnosis were eligible for inclusion. The planned dosages of cisplatin (mg/m2)/S-1 (mg/m2/day) were as follows: 40/80 (level 0); 50/80 (level 2); 60/80 (level 3). S-1 was orally administered twice daily from day 1 to 14 and day 29 to 42. Cisplatin was administered intravenously over 2 hours in each dosage of level at day 1 and 29. Radiation was delivered as a total dose of 50.4 Gy (28 fractions to 1.8 Gy). Dose-limiting toxicity (DLT) was a delay factor of the schedule due to incomplete recovery. (Response rate (RR) was evaluated according to the RECIST version 1.0.). Results: Twelve patients were enrolled, and level 1 was chosen as the starting dose. One of six patients developed DLTs at level 1, and the dose was escalated to level 2. DLTs occurred in two of six patients at level 2. As the MTD were determined as over 60 mg/m2, the RD were confirmed as level 2 for a subsequent phase II study. Conclusions: We determined the MTD and RD of cisplatin with concurrent S-1 and external beam radiation as neoadjuvant chemoradiotherapy for resectable BTC. Although further clinical trials are warranted to evaluate efficacy, this new regimen is potentially expected to become a standard neoadjuvant treatment for resectable BTC. Clinical trial information: 000009028.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 353
Phase I study of neoadjuvant S-1 plus cisplatin with concurrent radiation for biliary tract cancer (KOBTC02).
353 Background: Although surgery plays a key role in the curative treatment for biliary tract cancer (BTC), the prognosis is not satisfactory because of frequent postoperative recurrence. Multimodal treatment has been warranted in order to improve this situation. The aim of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of cisplatin as neoadjuvant chemoradiotherapy with S-1 and external beam radiation for BTC. Methods: Patients with resectable BTC at initial diagnosis were eligible for inclusion. The planned dosages of cisplatin (mg/m2)/S-1 (mg/m2/day) were as follows: 40/80 (level 0); 50/80 (level 2); 60/80 (level 3). S-1 was orally administered twice daily from day 1 to 14 and day 29 to 42. Cisplatin was administered intravenously over 2 hours in each dosage of level at day 1 and 29. Radiation was delivered as a total dose of 50.4 Gy (28 fractions to 1.8 Gy). Dose-limiting toxicity (DLT) was a delay factor of the schedule due to incomplete recovery. (Response rate (RR) was evaluated according to the RECIST version 1.0.). Results: Twelve patients were enrolled, and level 1 was chosen as the starting dose. One of six patients developed DLTs at level 1, and the dose was escalated to level 2. DLTs occurred in two of six patients at level 2. As the MTD were determined as over 60 mg/m2, the RD were confirmed as level 2 for a subsequent phase II study. Conclusions: We determined the MTD and RD of cisplatin with concurrent S-1 and external beam radiation as neoadjuvant chemoradiotherapy for resectable BTC. Although further clinical trials are warranted to evaluate efficacy, this new regimen is potentially expected to become a standard neoadjuvant treatment for resectable BTC. Clinical trial information: 000009028.
- Open Access
- 9 April 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 144
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature
An 83-year-old man underwent computed tomography during a routine check-up due to a history of surgical treatment for pancreatic cancer. Two tumors were detected in the anterior segment of the liver. A needle biopsy of the larger tumor was performed, and pathological examination showed that the tumor was a poorly differentiated hepatocellular carcinoma. Resection was not performed considering the patient’s poor physical condition. Thus, transcatheter arterial chemoembolization and radiofrequency ablation of the tumors were performed. Three months later, residual tumor of the larger lesion and multiple pulmonary metastases were detected. This time, continuous hepatic arterial infusion chemotherapy was performed. Although the pulmonary metastases markedly reduced, tumor thrombi appeared in the right portal vein on computed tomography. Finally, sorafenib was administered, which led to disappearance of the tumor thrombi and no other signs of recurrence 8 months after initiation of sorafenib on computed tomography. Although sorafenib administration has continued at reduced doses of 200 mg per day or less due to hypertension, complete response has persisted for the past 34 months. It is noteworthy that sorafenib has been given at reduced doses, but a long-term complete response is maintained in a patient who had portal tumor thrombi and distant metastasis. Herein, we present this rare case of advanced hepatocellular carcinoma controlled with reduced doses of sorafenib following multidisciplinary therapy, describe our single center experience with sorafenib use in patients with hepatocellular carcinoma, and review previous reports that focused on dose reduction of sorafenib.
- 9 April 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 144
Open AccessLong-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature
An 83-year-old man underwent computed tomography during a routine check-up due to a history of surgical treatment for pancreatic cancer. Two tumors were detected in the anterior segment of the liver. A needle biopsy of the larger tumor was performed, and pathological examination showed that the tumor was a poorly differentiated hepatocellular carcinoma. Resection was not performed considering the patient’s poor physical condition. Thus, transcatheter arterial chemoembolization and radiofrequency ablation of the tumors were performed. Three months later, residual tumor of the larger lesion and multiple pulmonary metastases were detected. This time, continuous hepatic arterial infusion chemotherapy was performed. Although the pulmonary metastases markedly reduced, tumor thrombi appeared in the right portal vein on computed tomography. Finally, sorafenib was administered, which led to disappearance of the tumor thrombi and no other signs of recurrence 8 months after initiation of sorafenib on computed tomography. Although sorafenib administration has continued at reduced doses of 200 mg per day or less due to hypertension, complete response has persisted for the past 34 months. It is noteworthy that sorafenib has been given at reduced doses, but a long-term complete response is maintained in a patient who had portal tumor thrombi and distant metastasis. Herein, we present this rare case of advanced hepatocellular carcinoma controlled with reduced doses of sorafenib following multidisciplinary therapy, describe our single center experience with sorafenib use in patients with hepatocellular carcinoma, and review previous reports that focused on dose reduction of sorafenib.
- 26 February 2015
- Published by Wiley in Hepatology Research
- Vol. 45 (12) , 1178-1184
Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus‐related cirrhosis
Recent randomized trials have failed to prove the benefit of steroid-free immunosuppression in liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Furthermore, there is a lack of data on the use of basiliximab in living donor liver transplantation (LDLT). This pilot study evaluated the safety and efficacy of a steroid minimization protocol using basiliximab compared with standard immunosuppression.A single center, prospective cohort analysis was conducted to compare two immunosuppression regimens in adult recipients who underwent LDLT for HCV since 2004: calcineurin inhibitor/mizoribine/basiliximab (the St- group) and calcineurin inhibitor/mizoribine/steroid (the St+ group). Study end-points were rejection rates, recurrent HCV, patient survival and other adverse events up to 2 years after transplantation.A total of 27 consecutive patients were enrolled. Transplantation characteristics were similar between the two groups (14 St- and 13 St+) except ABO incompatible cases being more common in the St+ group. Rejection rates, recurrent HCV, patient survival, fibrosis stage and new-onset diabetes mellitus at 2 years were comparable between the two groups. ABO incompatibility did not affect short- and long-term outcomes. Nine St- and seven St+ recipients underwent interferon and ribavirin therapy for recurrent HCV, with a sustained virological response rate of 33% and 29%, respectively.A steroid minimization protocol with basiliximab in adult LDLT for HCV is safe and affords equivalent rejection rates compared with standard immunosuppression. However, no significant differences are observed with respect to recurrent HCV, patient survival and metabolic complications.
- 26 February 2015
- Published by Wiley in Hepatology Research
- Vol. 45 (12) , 1178-1184
Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus‐related cirrhosis
Recent randomized trials have failed to prove the benefit of steroid-free immunosuppression in liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Furthermore, there is a lack of data on the use of basiliximab in living donor liver transplantation (LDLT). This pilot study evaluated the safety and efficacy of a steroid minimization protocol using basiliximab compared with standard immunosuppression.A single center, prospective cohort analysis was conducted to compare two immunosuppression regimens in adult recipients who underwent LDLT for HCV since 2004: calcineurin inhibitor/mizoribine/basiliximab (the St- group) and calcineurin inhibitor/mizoribine/steroid (the St+ group). Study end-points were rejection rates, recurrent HCV, patient survival and other adverse events up to 2 years after transplantation.A total of 27 consecutive patients were enrolled. Transplantation characteristics were similar between the two groups (14 St- and 13 St+) except ABO incompatible cases being more common in the St+ group. Rejection rates, recurrent HCV, patient survival, fibrosis stage and new-onset diabetes mellitus at 2 years were comparable between the two groups. ABO incompatibility did not affect short- and long-term outcomes. Nine St- and seven St+ recipients underwent interferon and ribavirin therapy for recurrent HCV, with a sustained virological response rate of 33% and 29%, respectively.A steroid minimization protocol with basiliximab in adult LDLT for HCV is safe and affords equivalent rejection rates compared with standard immunosuppression. However, no significant differences are observed with respect to recurrent HCV, patient survival and metabolic complications.
- Open Access
- 18 February 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 63
Usefulness of immunohistochemical studies in diagnosing metachronous gallbladder and small intestinal metastases from lung cancer with gastrointestinal hemorrhage: a case report
Isolated metachronous gastrointestinal metastases from advanced-stage lung cancer are rarely diagnosed on the basis of symptoms and resected. In this report, we present a case of resectable metachronous gallbladder and small intestinal metastases of lung cancer. An 86-year-old woman was treated for lung cancer with resection of the right inferior lobe. Five months after the surgery, she was re-admitted because of melena and anemia. Ultrasonography showed a gallbladder tumor with gastrointestinal hemorrhage, and laparoscopic-assisted cholecystectomy was subsequently performed. However, 2 months after this event, the patient presented again with melena and anemia and was diagnosed with a small intestinal tumor. Therefore, laparoscopic-assisted partial resection of the small intestine was performed. Immunohistochemical staining for thyroid transcription factor-1 and cytokeratin 7 confirmed that the two resected tumors were metachronous metastases of the primary lung cancer. The patient died of liver metastases 5 months after the last surgery. Our experience with this case suggests that surgical resection might not be curative but palliative for patients with isolated gallbladder and small intestinal metastases diagnosed on the basis of melena that is resistant to conservative treatment.
- 18 February 2015
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 13 (1) , 63
Open AccessUsefulness of immunohistochemical studies in diagnosing metachronous gallbladder and small intestinal metastases from lung cancer with gastrointestinal hemorrhage: a case report
Isolated metachronous gastrointestinal metastases from advanced-stage lung cancer are rarely diagnosed on the basis of symptoms and resected. In this report, we present a case of resectable metachronous gallbladder and small intestinal metastases of lung cancer. An 86-year-old woman was treated for lung cancer with resection of the right inferior lobe. Five months after the surgery, she was re-admitted because of melena and anemia. Ultrasonography showed a gallbladder tumor with gastrointestinal hemorrhage, and laparoscopic-assisted cholecystectomy was subsequently performed. However, 2 months after this event, the patient presented again with melena and anemia and was diagnosed with a small intestinal tumor. Therefore, laparoscopic-assisted partial resection of the small intestine was performed. Immunohistochemical staining for thyroid transcription factor-1 and cytokeratin 7 confirmed that the two resected tumors were metachronous metastases of the primary lung cancer. The patient died of liver metastases 5 months after the last surgery. Our experience with this case suggests that surgical resection might not be curative but palliative for patients with isolated gallbladder and small intestinal metastases diagnosed on the basis of melena that is resistant to conservative treatment.